Join us at SITC 2025

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, providing durable and even curative responses. However, most patients do not respond, and current biomarkers lack predictive accuracy. New approaches are needed to fully realize the potential of this field. This symposium will explore different strategies for the improved prediction of immunotherapy response and highlight new paths forward.

• Jérôme Galon, PhD, Director of the INSERM Laboratory Integrative Cancer Immunology and developer of Immunoscore, will provide a perspective of immune-based approaches to predict immunotherapy response.
• Janis Taube, MD, Professor at Johns Hopkins University and pioneer in the development and clinical application of PD-L1 as a predictive biomarker, will discuss recent advancements in response prediction.
• Hinco Gierman, PhD, Chief Scientific Officer at Elephas, will discuss a novel ex vivo cytokine profiling approach utilizing core needle biopsies to characterize patient response to ICI and share recent data demonstrating correlation of ex vivo cytokine response with clinical response.